Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Wholesale: Comprehensive Analysis Of Production, Purity Standards, And Industrial Applications

NOV 17, 202655 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine phosphate (phosphocreatine) represents a critical high-energy phosphate compound extensively utilized in pharmaceutical formulations, sports nutrition, and therapeutic interventions for cardiovascular and neuromuscular disorders. As a wholesale commodity, creatine phosphate demands rigorous quality control, scalable synthesis methodologies, and compliance with international pharmaceutical standards. This article provides an in-depth examination of enzymatic and chemical synthesis routes, purification protocols achieving >99% purity, regulatory frameworks governing bulk distribution, and emerging applications in regenerative medicine and neuroprotection, tailored for R&D professionals engaged in process optimization and commercial-scale manufacturing.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Biochemical Significance Of Creatine Phosphate

Creatine phosphate (N-[aminoiminomethyl]-N-methylglycine phosphate, CAS 67-07-2) functions as the primary cellular energy buffer in vertebrate muscle and neural tissues, reversibly donating its phosphoryl group to adenosine diphosphate (ADP) via the creatine kinase (CK) reaction to regenerate adenosine triphosphate (ATP)15. The compound exists predominantly as a zwitterionic species at physiological pH (pKa ~4.5 for the phosphate group), with molecular weight 211.04 g/mol in its anhydrous form and 327.18 g/mol as the disodium salt tetrahydrate commonly used in pharmaceutical preparations89.

The phosphoramidate bond (P-N) in creatine phosphate exhibits a standard free energy of hydrolysis (ΔG°') of approximately -43.1 kJ/mol, positioning it above ATP (-30.5 kJ/mol) in the cellular energy hierarchy110. This thermodynamic property enables efficient ATP regeneration during periods of high metabolic demand, such as intense muscular contraction or neuronal firing. Structural analogs including cyclocreatine and phosphocreatine prodrugs have been synthesized to enhance membrane permeability and bioavailability, with modifications at the guanidino or carboxyl moieties234.

Key physicochemical properties relevant to wholesale handling include:

  • Solubility: Highly soluble in water (>500 g/L at 25°C for disodium salt), sparingly soluble in ethanol (<5 g/L), insoluble in non-polar solvents8
  • Stability: Susceptible to hydrolysis at pH <3 or >9; optimal storage at pH 6.5–7.5, 2–8°C, protected from light and moisture17
  • Melting point: Decomposes above 200°C without distinct melting (anhydrous form); calcium salt exhibits decomposition at 243–244°C812
  • Hygroscopicity: Disodium salt tetrahydrate readily absorbs atmospheric moisture; requires sealed packaging with desiccants for bulk storage715

Understanding these molecular characteristics is essential for designing robust synthesis, purification, and formulation strategies that preserve compound integrity throughout the supply chain.

Synthesis Methodologies For Industrial-Scale Creatine Phosphate Production

Enzymatic Phosphorylation Routes

The enzymatic synthesis of creatine phosphate leverages the reversibility of the creatine kinase reaction, offering high regio- and stereoselectivity unattainable via purely chemical methods1. The classical approach involves incubating creatine with 3-phosphoglyceric acid (3-PGA) as phosphate donor in the presence of aqueous muscle extract (containing endogenous CK, phosphoglycerate kinase, and adenylate kinase) and a catalytic quantity of ATP (typically 0.1–1.0 mM)1. The reaction proceeds optimally at pH 9.0–10.5 (maintained via NaOH or KOH addition), 25–37°C, with molar ratios of creatine:3-PGA:ATP of approximately 1:1.2:0.011.

Critical process parameters include:

  • Enzyme source: Rabbit or bovine skeletal muscle extracts provide CK activity of 50–200 U/mg protein; recombinant human CK isoforms (CK-MM, CK-MB) offer defined activity but higher cost110
  • Reaction time: 2–6 hours to achieve >85% conversion; prolonged incubation (>12 h) risks product degradation via non-enzymatic hydrolysis1
  • Termination: Brief heating to 70–100°C for 5–10 minutes denatures enzymes and halts side reactions, followed by rapid cooling to <10°C1
  • Yield: Enzymatic routes typically achieve 60–85% isolated yield based on creatine input, with purity >92% before final purification18

A significant advantage of enzymatic synthesis is the elimination of toxic reagents such as phosphoryl chloride (POCl₃), reducing environmental burden and simplifying downstream purification17. However, the requirement for expensive ATP and purified enzymes limits cost-competitiveness for bulk production, making this route more suitable for high-purity pharmaceutical-grade material or research quantities1.

Chemical Phosphorylation Strategies

Chemical synthesis of creatine phosphate traditionally employs phosphoryl chloride (POCl₃) or phosphorus pentoxide (P₂O₅) as phosphorylating agents, reacting with creatine or protected creatine derivatives under anhydrous conditions712. The reaction of creatine with POCl₃ in anhydrous pyridine at -10 to 0°C yields creatine phosphate via nucleophilic attack of the guanidino nitrogen on the electrophilic phosphorus center12:

Creatine + POCl₃ → Creatine-PO₃Cl₂ (intermediate) → Creatine Phosphate + HCl

Key challenges include:

  • Regioselectivity: Competing O-phosphorylation at the carboxyl group necessitates protection strategies (e.g., esterification) or careful pH control during workup712
  • Hydrolysis sensitivity: Trace moisture converts POCl₃ to phosphoric acid, reducing yield and introducing impurities; reactions must be conducted under rigorously anhydrous conditions (<50 ppm H₂O)12
  • Purification complexity: Byproducts including inorganic phosphates, pyridinium salts, and unreacted creatine require multi-step ion-exchange chromatography or recrystallization78

An improved protocol involves pre-forming protected creatinol sulfate by reacting creatinol with sulfuric acid, followed by phosphorylation with POCl₃, ClPO₃H₂, or P₂O₅ at 50–70°C12. This approach achieves 60–85% yield with >99% purity after recrystallization from water-ethanol mixtures12. The overall reaction sequence is:

Creatinol + H₂SO₄ → Protected Creatinol Sulfate Protected Creatinol Sulfate + POCl₃ → Creatinol O-Phosphate + HCl + H₂SO₄

Post-reaction workup involves neutralization with sodium hydroxide to pH 6.5–7.0, precipitation of the disodium salt, and washing with cold ethanol or butanone to remove colored impurities812. Final recrystallization from hot water (50–70°C) followed by vacuum filtration yields pharmaceutical-grade creatine phosphate with purity 99.05–99.8% as determined by HPLC12.

Comparative Economics And Scalability

For wholesale production (>100 kg batches), chemical synthesis via POCl₃ remains the dominant route due to lower reagent costs ($2–5/kg creatine phosphate vs. $15–30/kg for enzymatic routes) and established infrastructure712. However, enzymatic methods are gaining traction for specialty applications requiring ultra-high purity (>99.5%) or specific isotopic labeling (e.g., ¹⁵N, ¹³C-enriched material for metabolic studies)1. Hybrid approaches combining enzymatic synthesis with chemical purification (e.g., ion-exchange chromatography on strongly anionic resins) offer a compromise, achieving 95–98% purity at intermediate cost8.

Purification Protocols And Quality Control Standards For Wholesale Creatine Phosphate

Ion-Exchange Chromatography

The isolation of creatine phosphate ions from crude reaction mixtures employs strongly anionic resins (e.g., Dowex 1×8, Amberlite IRA-400 in Cl⁻ or OH⁻ form) to selectively bind the negatively charged phosphate moiety while allowing neutral creatine and cationic impurities to elute8. The process involves:

  1. Loading: Crude phosphorylation suspension adjusted to pH 7.0–8.0 is passed through a resin column (bed volume 5–10× sample volume) at flow rates of 1–3 bed volumes/hour8
  2. Washing: Sequential washes with deionized water (3–5 bed volumes) remove unbound creatine, salts, and organic solvents8
  3. Elution: Creatine phosphate is displaced using 0.5–2.0 M NaCl or 0.1–0.5 M HCl gradients, with peak fractions identified via UV absorbance at 210 nm or phosphate assay (molybdate method)8
  4. Desalting: Eluate is concentrated under vacuum (<40°C) and desalted via size-exclusion chromatography (Sephadex G-10) or dialysis (MWCO 500 Da)8

This method achieves >95% recovery with purity 92–97%, suitable for further crystallization8. For analytical-scale purification, HPLC on anion-exchange columns (e.g., Dionex CarboPac PA1) with isocratic 50 mM NaOH elution provides baseline separation of creatine phosphate from creatine, inorganic phosphate, and ATP in <15 minutes18.

Recrystallization Techniques

The final purification step exploits the differential solubility of creatine phosphate salts in aqueous-organic solvent systems712. A representative protocol for the disodium salt tetrahydrate involves:

  • Dissolving crude creatine phosphate (92–95% purity) in minimal hot water (50–70°C, 6–10 mL/g)712
  • Filtering the hot solution through activated charcoal (0.5–1% w/v) to remove colored impurities and endotoxins7
  • Cooling to 0–5°C over 2–4 hours to induce crystallization; seeding with pure crystals accelerates nucleation712
  • Vacuum filtration and washing with ice-cold ethanol (2×) or butanone (2×) until eluate is colorless712
  • Drying under vacuum (<1 mbar) at 40–50°C for 12–24 hours to constant weight12

This procedure yields creatine phosphate with purity 99.05–99.8% (HPLC), residual water content <0.5% (Karl Fischer titration), and endotoxin levels <0.5 EU/mg (LAL assay)12. For the calcium salt (used in certain injectable formulations), precipitation from aqueous solution at pH 6.5–7.0 with CaCl₂ followed by recrystallization from water-ethanol (3:1 v/v) affords material with melting point 243–244°C and purity >99%812.

Analytical Characterization And Specifications

Wholesale creatine phosphate must meet stringent pharmacopeial standards (USP, EP, JP) encompassing:

  • Identity: ¹H-NMR (D₂O, 400 MHz) showing characteristic signals at δ 3.03 (s, 3H, N-CH₃), 3.92 (s, 2H, CH₂); ³¹P-NMR at δ 2.5–3.0 ppm (referenced to 85% H₃PO₄)912
  • Purity: HPLC (anion-exchange, UV 210 nm) ≥99.0% main peak; total impurities (creatine, creatinine, inorganic phosphate) <1.0%12
  • Water content: 18.0–22.0% for tetrahydrate (theoretical 21.7%), <0.5% for anhydrous form (Karl Fischer)12
  • Heavy metals: Pb <10 ppm, As <2 ppm, Hg <1 ppm (ICP-MS)7
  • Microbial limits: Total aerobic count <10³ CFU/g, yeast/mold <10² CFU/g, absence of E. coli and Salmonella (USP <61>/<62>)7
  • Endotoxin: <0.5 EU/mg for parenteral formulations (USP <85>)12

Advanced techniques such as capillary electrophoresis (CE) and ion chromatography (IC) provide orthogonal purity assessment, resolving closely related phosphorylated metabolites (ADP, AMP, pyrophosphate) that may co-elute in HPLC18.

Regulatory Frameworks And Compliance For Bulk Distribution

Pharmaceutical-Grade Material

Creatine phosphate intended for injectable or oral pharmaceutical formulations must comply with Good Manufacturing Practice (GMP) regulations (FDA 21 CFR Part 211, EMA EudraLex Volume 4) and be sourced from facilities holding Drug Master Files (DMF) or Certificates of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM)71314. Key regulatory requirements include:

  • Starting material qualification: Creatine and phosphorylating agents must meet pharmacopeial monographs (USP, EP) or be accompanied by Certificates of Analysis (CoA) demonstrating compliance with ICH Q7 guidelines7
  • Process validation: Three consecutive commercial-scale batches demonstrating reproducible yield (RSD <5%), purity (≥99.0%), and impurity profile712
  • Stability data: Real-time and accelerated stability studies (ICH Q1A) showing <2% degradation over 24 months at 25°C/60% RH and 6 months at 40°C/75% RH715
  • Extractables/leachables: Assessment of potential contaminants from packaging materials (glass vials, rubber stoppers) per USP <1663> and <1664>7

Pharmaceutical preparations combining creatine phosphate with creatine phosphokinase (creatine kinase) for enhanced bioavailability have been described, requiring additional enzyme activity assays (U/mg protein) and sterility testing for parenteral formulations1314.

Nutraceutical And Sports Nutrition Applications

Creatine phosphate marketed as a dietary supplement falls under less stringent regulations (FDA DSHEA, EU Regulation 1924/2006) but must adhere to Good Manufacturing Practice for dietary supplements (21 CFR Part 111) and carry appropriate labeling disclaimers5615. Key considerations include:

  • Identity and purity: Third-party certification (NSF Certified for Sport, Informed-Choice) verifying absence of banned substances (anabolic steroids, stimulants) and compliance with label claims (±10% of declared content)15
  • Dosage forms: Tablets, capsules, and powders must meet USP dissolution standards (≥80% release in 30 minutes for immediate-release forms) and disintegration times (<30 minutes)15
  • Stability: Formulations incorporating dicalcium phosphate, polyvinylpyrrolidone, and shellac coatings
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
BOEHRINGER MANNHEIM GMBHPharmaceutical-grade creatine phosphate manufacturing for injectable formulations and high-purity research applications requiring >99% purity and compliance with GMP standards.Enzymatic Creatine Phosphate Production SystemAchieves 60-85% isolated yield through enzymatic phosphorylation using muscle extract with creatine kinase, eliminating toxic phosphoryl chloride and simplifying downstream purification compared to chemical synthesis routes.
XENOPORT INC.Therapeutic interventions for ischemia, heart failure, neurodegenerative disorders, and cardiovascular conditions requiring rapid intracellular energy restoration.Membrane Permeable Creatine Phosphate ProdrugsEnhanced membrane permeability and bioavailability through structural modifications at guanidino or carboxyl moieties, enabling efficient cellular uptake and ATP regeneration in energy-deficient tissues.
BASF AKTIENGESELLSCHAFTSports nutrition supplements and pharmaceutical formulations requiring high-purity creatine (>99%) with optimal handling properties for bulk distribution and consumer applications.High-Purity Creatine Purification ProcessProduces creatine monohydrate crystals with reduced fines content and coarser particle size through controlled dissolution and recrystallization, minimizing dust formation and electrostatic charging while achieving pharmaceutical-grade purity.
TIANJIN TIANCHENG PHARMACEUTICAL CO. LTD.Industrial-scale production of creatinol O-phosphate for cardiovascular and neuromuscular therapeutic applications requiring stringent quality control and regulatory compliance.Creatinol O-Phosphate Chemical SynthesisAchieves 60-85% yield and 99.05% purity through protected creatinol sulfate intermediate pathway using POCl3, with melting point 243-244°C verified by HPLC analysis and re-crystallization protocols.
STAB. CHIMICI FARM. RIUN. SCHIAPPARELLIPharmaceutical preparations for parenteral administration in cardiac surgery pre-treatment, angina therapy, and acute energy metabolism support in clinical settings.Calcium Salt Creatine Phosphate PurificationIsolates creatine phosphate ions via strongly anionic resin chromatography followed by calcium salt precipitation, achieving high purity suitable for therapeutic injectable formulations with controlled impurity profiles.
Reference
  • Process for the preparation of creatine phosphate
    PatentInactiveUS3639211A
    View detail
  • Creatine phosphate prodrugs, compositions and uses thereof
    PatentWO2007146085A2
    View detail
  • Creatine phosphate analog prodrugs, compositions and uses thereof
    PatentInactiveUS8202852B2
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png